Loading...
•
Sep 30, 2022
C4 Therapeutics Q3 2022 Earnings Report
Reported third quarter financial results and recent business highlights.
Key Takeaways
C4 Therapeutics reported a net loss of $32.0 million for the third quarter of 2022, with revenue of $6.8 million. The company's cash, cash equivalents, and marketable securities totaled $366.0 million as of September 30, 2022, expected to provide runway to the end of 2024.
Advanced Enrollment in Phase 1/2 Clinical Trial of CFT7455 and CFT8634
IND Clearance Achieved for CFT1946, a BRAF-V600 BiDAC Degrader; On Track to Initiate the Phase 1/2 Clinical Trial by Year-End
Cash, Cash Equivalents and Marketable Securities Total $366.0 million as of September 30, 2022; Expected to Provide Runway to End of 2024
Received FDA clearance of the investigational new drug application for Phase 1/2 clinical trial of CFT1946, which is expected to initiate by year-end
Revenue by Segment
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of September 30, 2022, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...